ChinaHealthcare and life sciences2025 – ongoingInnovent Biologics
AI-driven de novo design of small-protein drugs
Innovent reported improved candidate hit rates with AI-designed small-protein drugs
Problem
Small-protein drug research required repeated candidate design and optimization. Innovent sought faster research iterations and better candidate hit rates.
Approach
Innovent built a closed-loop AI system for de novo small-protein design. It covered target elucidation through molecular optimization and was used in internal projects.
Results
No published figures
Takeaway
The reported improvements concerned internal research. Innovent did not disclose numerical hit rates or iteration times.
Categories
- Industry
- Healthcare and life sciences
- Business function
- IT and R&D
- Innovation type
- Process innovation
- AI technology
- Generative AI
- Adoption
- Built in-house
- Evidence
- Company's own claim
Sources
Source summaries
Innovent described its small-protein design system operating in internal projects. It claimed improved candidate hit rates and faster research iterations without precise figures.
Full details are in the original sources.